###### Key messages

What is already known about this subject?
=========================================

-   The first European League Against Rheumatism (EULAR) recommendations for the management of hand osteoarthritis were published in 2007, based on expert opinion and available literature at that time.

What does this study add?
=========================

-   Since 2007 many new trials were published in the hand osteoarthritis field.

-   This systematic literature review provides an updated overview of the current evidence on efficacy and safety of non-pharmacological, pharmacological and surgical treatment options for hand osteoarthritis.

How might this impact on clinical practice?
===========================================

-   This systematic literature review informed the task force for the 2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Introduction {#s1}
============

In 2007, the first European League Against Rheumatism (EULAR) recommendations for the management of hand osteoarthritis (OA) were published, based on expert opinion and an overview of the literature.[@R1] Many propositions, however, were based mainly on expert opinion, as evidence was lacking.

Despite it being a prevalent disease, for years, options to treat patients with hand OA have been limited. In search of better alternatives for symptom relief, and in hopes of finding a disease-modifying anti-osteoarthritic drug, many clinical trials have been performed in the last decade, expanding the possible range of therapeutic options. At the same time, data have become available showing that some treatments which were believed to be beneficial do not appear to be efficacious after all. New evidence has emerged on various therapies, including but not limited to self-management, application of thumb base splints, topical non-steroidal anti-inflammatory drugs (NSAIDs), oral corticosteroids, various intra-articular therapies and treatment with conventional and biological disease-modifying anti-rheumatic drugs (cs/bDMARDs), for example, hydroxychloroquine and tumour necrosis factor (TNF) inhibitors.

In light of the newly accrued data, it was therefore time to update the 2007 management recommendations. This paper presents the systematic literature review (SLR) that accompanies the update of the recommendations. The aim of this SLR was to inform the task force on the current evidence for efficacy and safety of all non-pharmacological, pharmacological and surgical treatments for hand OA.

Methods {#s2}
=======

Search strategy {#s2-1}
---------------

A systematic search was conducted in PubMed/MEDLINE, Embase and the Cochrane CENTRAL databases up to 6 June 2017. Additionally, conference abstracts of the EULAR, American College of Rheumatology (ACR) and OsteoArthritis Research Society International (OARSI) annual conferences of the last two years, and reference lists of included studies and other relevant SLRs were screened. The search strategy can be found in the [online supplementary file 1](#SP1){ref-type="supplementary-material"}. Eligible study types were randomised controlled trials (RCTs) and clinical controlled trials (CCTs). Observational longitudinal studies were considered to assess safety, and to assess efficacy of surgical interventions, but only if a comparator group was available and the number of participants per group was at least 50. Cochrane systematic reviews were also included. The following hierarchy of study design was adopted to assess the evidence for each intervention: Cochrane systematic reviews, RCTs, CCTs and lastly observational studies.
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Research questions were formulated according to the PICO format: Participants, Interventions, Comparators, Outcomes.[@R2] Studies of any non-pharmacological, pharmacological or surgical intervention in adults diagnosed with hand OA were included. Studies including participants with other diagnoses were only eligible for inclusion if the results were presented separately for participants with hand OA. The comparator could be placebo, care-as-usual, any other non-pharmacological, pharmacological or surgical intervention, or the same intervention in a different dose, formulation, regimen or treatment duration. Studies without a comparator were excluded. Other exclusion criteria were a total number of participants in non-surgical trials \<20 and premature termination of the trial.

Efficacy outcomes were considered as proposed by the OMERACT core set for domains in clinical trials for hand OA.[@R3] Main efficacy outcomes were pain (preferably measured on visual analogue scale (VAS), numerical rating scale (NRS), or a validated questionnaire, eg, Australian/Canadian Hand Osteoarthritis Index (AUSCAN) or Michigan Hand Outcomes Questionnaire (MHQ)), hand function (validated questionnaire, eg, Functional Index for Hand OsteoArthritis (FIHOA), AUSCAN or MHQ) and hand strength (grip or pinch strength). Additional efficacy outcomes that were considered included patient global assessment (VAS or NRS), health-related quality of life (Short-Form 36, EuroQoL), structural damage, hand mobility (Hand Mobility in Scleroderma test, modified Kapandji index, fingertip-to-palm-distance) and the number of participants fulfilling the OMERACT-OARSI responder criteria.[@R4] The primary safety outcome was withdrawals due to adverse events (AEs). In addition, serious AEs and AEs broken up by bodily system (eg, gastrointestinal, cardiovascular) were assessed. Studies that did not assess any efficacy or safety outcomes were excluded.

Study selection, data extraction and risk of bias assessment {#s2-2}
------------------------------------------------------------

One reviewer (FK) screened titles and abstracts to determine eligibility for inclusion, according to predefined inclusion criteria, followed by full-text review where necessary. In case of doubt, a second reviewer was consulted (MK/LC). Relevant data on study characteristics, interventions, study population and the above-mentioned outcomes was extracted (FK). The risk of bias (RoB) was assessed with regard to random sequence generation, allocation concealment, blinding (participants, care provider, outcome assessor), incomplete outcome data, selective outcome reporting and other sources of bias according to the 'Cochrane tool' (FK).[@R5] Each item was judged as low (green colour), high (red) or unclear RoB (yellow; lack of information or uncertainty over potential bias). An 'overall assessment' for each study was based on the judgements for each RoB item. Selection bias (sequence generation, allocation concealment) and blinding were considered 'key domains', that is, the most important domains in a study's RoB.

Data analysis {#s2-3}
-------------

Data were only pooled in case of sufficient clinical and statistical homogeneity. For continuous outcomes, data were summarised as mean difference (MD) with corresponding 95% CI, unless different measurement instruments were used to measure the same outcome, in which case standardised mean differences were calculated. A random effects model was used. Studies that could not be included in the meta-analysis are presented descriptively. Stata V.14.1 was used for meta-analysis.

Results {#s3}
=======

The literature search yielded 5020 records (after de-duplication), of which 127 references were included in this review (see [figure 1](#F1){ref-type="fig"} and [online supplementary table S1](#SP1){ref-type="supplementary-material"}). Three studies were additionally excluded because of language (Turkish, Chinese). In total, 50 studies assessed benefits and harms of different non-pharmacological therapies, including one Cochrane review. Pharmacological interventions were investigated in 64 studies, including one observational study. Surgical interventions were assessed in 11 trials, all summarised in one Cochrane review.

![Flow chart of systematic literature review. ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; OARSI, Osteoarthritis Research Society International.](rmdopen-2018-000734f01){#F1}

Non-pharmacological interventions {#s3-1}
---------------------------------

[Table 1](#T1){ref-type="table"} presents an overview of the characteristics and RoB of the 28 studies of the most relevant non-pharmacological interventions to inform the 2018 update of the EULAR management recommendations for hand OA. The remaining trials studied thermal modalities (n=3), manual therapy (n=3), balneotherapy (n=6), low-level laser therapy (n=4), yoga (n=1), nuclear magnetic resonance (n=1), magnetotherapy (n=1), leeches (n=1) and alkalinisation of diet (n=1), and are described in [online supplementary tables (3.1.5, 3.1.7, 3.1.9, 3.1.11)](#SP1){ref-type="supplementary-material"}.

###### 

Characteristics of studies of main non-pharmacological interventions (n=28 studies)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RoB                                                                                                        Study                              Design                                                                                         Intervention                                                                        Frequency, duration (instructions)        N                                               OA location, definition                          Women (%)     Age (years)                                Primary outcome
  ---------------------------------------------------------------------------------------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------- ------------------------------------------------ ------------- ------------------------------------------ ------------------------------------------
  **Exercise**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                             Østeras *et al* 2017[@R6]﻿         SLR\                                                                                           Hand exercise vs no exercise (N=6); different CMC exercise programme (N=1)          6--12 months                              534                                             Hand (6) or CMC (1), ACR or clinical diagnosis   Median 90     Mean 60--81                                --
                                                                                                                                                (6 RCT,\                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                1 CO)                                                                                                                                                                                                                                                                                                                                                                                  

  **Joint protection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                             Dziedzic *et al* 2015[@R7]         Factorial RCT                                                                                  Group-based joint protection programme (including splints) (JP+, HEx--)             4 sessions in 4 weeks                     62                                              ACR                                              69            65.5 (8.6)                                 OARSI-OMERACT responder

  Group-based exercise programme(HEx+, JP--)                                                                 65                                                                                                                                63                                                                                  64.5 (9.0)                                                                                                                                                                                          

  Group-based combination programme: education, joint protection (including splints), exercise (JP+, HEx+)   65                                                                                                                                71                                                                                  66.0 (9.3)                                                                                                                                                                                          

  Education alone (JP--, HEx--)                                                                              4 weeks                            65                                                                                                                                                                                 62                                        67.2 (9.5)                                                                                                                                                

  **Splints**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                             Adams *et al* 2014[@R8]\           RCT                                                                                            Splint+occupational therapy                                                         4 weeks (NR)                              9                                               CMC, NR                                          78            61.2 (9.4)                                 AUSCAN pain
                                                                                                             (A)                                                                                                                                                                                                                                                                                                                                                                                                                       

  Placebo splint+occupational therapy                                                                        9                                                                                                                                                                                                                                                                                                                                                                                                                         

  Occupational therapy only                                                                                  9                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                             Arazpour *et al* 2016[@R9]         RCT                                                                                            Splint (custom-made, thermoplast, CMC)                                              4 weeks (use during ADLs, not at night)   16                                              CMC, clinical diagnosis and E-L stage I--II      87            50.2 (5.7)                                 NR

  No intervention                                                                                            9                                  88                                                                                             52.3 (6.4)                                                                                                                                                                                                                                                                              

  Bani *et al* 2013[@R16]                                                                                    CO (WA+)                           Splint (custom-made, thermoplast)                                                              4 weeks (use during ADLs, not at night)                                             24                                        CMC, clinical diagnosis and E-L stage I-II      67                                               53.4          NR                                         

  Splint (prefabricated, neoprene, CMC/MCP)                                                                  75                                 54.9                                                                                                                                                                                                                                                                                                                                                                                   

  No intervention                                                                                            4 weeks                            11                                                                                             73                                                                                  58.6                                                                                                                                                                                                

  Becker,*et al* 2013[@R13]                                                                                  RCT                                Splint (custom-made, thermoplast, CMC/MCP)                                                     8--10 weeks (use as needed during ADLs and at night)                                58                                        CMC, clinical diagnosis                         80                                               62.8 (7.7)    DASH                                       

  Splint (prefabricated, neoprene, CMC)                                                                      61                                 75                                                                                             63.3 (8.5)                                                                                                                                                                                                                                                                              

  Cantero-Tellez *et al* 2016[@R14]                                                                          CCT                                Splint (custom-made, thermoplast, CMC/MCP)                                                     12 weeks (use during ADLs (3--4 hours/day) and at night)                            44                                        CMC, clinical and Rx diagnosis                  93                                               59.7 (9.6)    NR                                         

  Splint (custom-made, thermoplast, CMC)                                                                     40                                 90                                                                                             60.5 (9.8)                                                                                                                                                                                                                                                                              

  Gomes-Carreira 2010[@R10]                                                                                  RCT                                Splint (custom-made, CMC/MCP)                                                                  12 weeks (NR)                                                                       20                                        CMC, clinical diagnosis and E-L stage II--III   100                                              62.8 (8.5)    VAS pain                                   

  No intervention                                                                                            20                                 90                                                                                             65.1 (10.1)                                                                                                                                                                                                                                                                             

                                                                                                             Hermann *et al* 2013[@R11]         RCT                                                                                            Splint+hand exercises (prefabricated, fabrifoam, CMC/MCP)                           8 weeks (use as needed)                   30                                              CMC, ACR, thumb pain                             97            70.7 (7.3)                                 NRS pain

  Hand exercises                                                                                             29                                 100                                                                                            70.2 (6.2)                                                                                                                                                                                                                                                                              

  Rannou *et al* 2009[@R12]                                                                                  RCT                                Splint (custom-made, neoprene, CMC/MCP)                                                        1 year (use at night)                                                               57                                        CMC, clinical and Rx diagnosis                  93                                               63.0 (7.9)    VAS pain                                   

  Usual care                                                                                                 55                                 85                                                                                             63.5 (7.6)                                                                                                                                                                                                                                                                              

  ﻿Sillem *et al* ﻿2011[@R17]                                                                                CO (WA+)                           Splint (custom-made, neoprene, CMC/MCP)                                                        4 weeks (use when symptomatic, during heavy tasks and at night if preferred)        56                                        CMC, clinical diagnosis                         91                                               64.1 (8.6)    AUSCAN function                            

  Splint (prefabricated, neoprene, IP to wrist)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Wajon *et al* 2005[@R15]                                                                                   RCT                                Splint (custom-made, thermoplast, CMC)+abduction exercise regimen                              2 weeks splint only, 4 weeks splint +exercise (use full-time)                       19                                        CMC, clinical diagnosis and E-L stage I--III    74                                               59.7 (9.0)    NR                                         

  Splint (custom-made, thermoplast, CMC/MCP)+pinch exercise regimen                                          21                                 81                                                                                             61.2 (12.5)                                                                                                                                                                                                                                                                             

  Watt *et al*\                                                                                              CCT                                Splint (custom-made, thermoplast, DIP)                                                         12 weeks (use at night)                                                             26                                        DIP, ACR, Rx damage DIP                         88                                               63 (51--78)   NRS pain                                   
  2014[@R21]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  No intervention                                                                                            26                                                                                                                                                                                                                                                                                                                                                                                                                        

  Weiss *et al*\                                                                                             CO\                                Splint (custom-made, thermoplast, CMC)                                                         1 week (use when symptomatic)                                                       26                                        CMC, clinical and Rx diagnosis                  81                                               57 (36--88)   NR                                         
  2000[@R19]                                                                                                 (WA--)                                                                                                                                                                                                                                                                                                                                                                                                                    

  Splint (custom-made, thermoplast, CMC to wrist)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Weiss *et al*\                                                                                             CO\                                Splint (custom-made, thermoplast, CMC)                                                         1 week (use when symptomatic)                                                       25                                        CMC, clinical diagnosis and E-L stage I--II     84                                               NR            NR                                         
  2004[@R20]                                                                                                 (WA--)                                                                                                                                                                                                                                                                                                                                                                                                                    

  Splint (prefabricated, neoprene, CMC/MCP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Van der Vegt *et al*\                                                                                      CO (WA+)                           Splint (custom-made, thermoplast, CMC/MCP)                                                     2 weeks (NR)                                                                        63                                        CMC, clinical and Rx diagnosis                  70                                               60.1 (8.2)    VAS pain                                   
  2017[@R18]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Splint (prefabricated, semirigid, CMC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Assistive devices**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                             Kjeken *et al*\                    RCT                                                                                            Provision of assistive devices+information                                          12 weeks (NR)                             35                                              ACR                                              97            61.1 (6.0)                                 COPM
                                                                                                             2011[@R22]                                                                                                                                                                                                                                                                                                                                                                                                                

  Information alone                                                                                          35                                 97                                                                                             59.9 (7.5)                                                                                                                                                                                                                                                                              

  **Combination** **programme**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                             Boustedt\                          RCT                                                                                            Group-based combination programme: education, joint protection, exercise, splints   10 sessions in 5 weeks                    22                                              CMC, clinical and Rx diagnosis                   100           61 (40--76)                                NR
                                                                                                             2009[@R23]                                                                                                                                                                                                                                                                                                                                                                                                                

  Group-based joint protection programme                                                                     20                                 61 (50--76)                                                                                                                                                                                                                                                                                                                                                                            

  Dziedzic,*et al*\                                                                                          Factorial RCT                      Group-based joint protection programme (including splints) (JP+, HEx--)                        4 sessions in 4 weeks                                                               62                                        ACR                                             69                                               65.5 (8.6)    OARSI-OMERACT responder                    
  2015[@R7]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Group-based exercise programme (HEx+, JP--)                                                                65                                 63                                                                                             64.5 (9.0)                                                                                                                                                                                                                                                                              

  Group-based combination programme: education, joint protection (including splints), exercise (JP+, HEx+)   65                                 71                                                                                             66.0 (9.3)                                                                                                                                                                                                                                                                              

  Education alone (JP--, HEx--)                                                                              4 weeks                            65                                                                                             62                                                                                  67.2 (9.5)                                                                                                                                                                                          

                                                                                                             Perez-Marmol *et al*\              RCT                                                                                            Fine motor skills occupational therapy                                              24 sessions in 8 weeks                    25                                              Clinical diagnosis                               84            82.8 (8.3)                                 DASH
                                                                                                             2017[@R24]                                                                                                                                                                                                                                                                                                                                                                                                                

  Conventional occupational therapy                                                                          23                                 74                                                                                             79.2 (10)                                                                                                                                                                                                                                                                               

                                                                                                             Stamm *et al*\                     CCT                                                                                            Individual combination programme: education, joint protection, exercise             Single session, 3 months                  20                                              ACR                                              85            60.5 (8.3)                                 Grip strength
                                                                                                             2002[@R25]                                                                                                                                                                                                                                                                                                                                                                                                                

  Education alone                                                                                            3 months                           20                                                                                             90                                                                                  60.4 (6.4)                                                                                                                                                                                          

  Stukstette *et al* 2013[@R26]                                                                              RCT                                Group-based combination programme: education, joint protection (including splints), exercise   4 sessions in 12 weeks                                                              76                                        ACR                                             82                                               60 (7)        AUSCAN function, OARSI-OMERACT responder   

  Education alone                                                                                            12 weeks                           75                                                                                             84                                                                                  58 (9)                                                                                                                                                                                              

                                                                                                             Stukstette *et al* 2014[@R27](A)   RCT                                                                                            Group-based booster session after combination programme[@R26]                       Single session, 1 year                    147                                             ACR                                              84            59 (8)                                     AUSCAN function, OARSI-OMERACT responder

  No booster session after combination programme[@R26]                                                       1 year                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                             Villafane 2013[@R28]               RCT                                                                                            Individual combination programme: manual therapy, exercise                          12 sessions in 4 weeks                    30                                              CMC, clinical diagnosis and Rx damage            90            82 (2)                                     VAS pain

  Sham intervention (non-therapeutic ultrasound of the thumb region)                                         30                                 80                                                                                             83 (1)                                                                                                                                                                                                                                                                                  

  Wajon 2005[@R15]                                                                                           RCT                                Splint (custom-made, thermoplast, CMC)+abduction exercise regimen                              2 weeks splint only, 4 weeks splint+excercise; use full-time                        19                                        CMC, clinical diagnosis and E-L stage I--III    74                                               59.7 (9.0)    NR                                         

  Splint (custom-made, thermoplast, CMC/MCP)+pinch exercise regimen                                          21                                 81                                                                                             61.2 (12.5)                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are mean (SD) or median (min--max). Colours denote RoB (green: low, yellow: unclear, red: high). (A) indicates conference abstract.

ACR, American College of Rheumatology; ADLs, activities of daily living; AUSCAN, Australian/Canadian Hand Osteoarthritis Index; CMC, first carpometacarpal joint; CO, cross-over trial; COPM, Canadian Occupational Performance Measure; DASH, Disabilities of the Arm, Shoulder and Hand; DIP, distal interphalangeal joint; E-L, Eaton-Litter; FIHOA, Functional Index for Hand OsteoArthritis; IP, interphalangeal joint; MCP, metacarpophalangeal; N, number; NR, not reported; NRS, numerical rating scale; OA, osteoarthritis; RCT, randomised controlled trial; RoB, risk of bias; Rx, radiography; SLR, systematic literature review; VAS, visual analogue scale; WA, wash-out period.

The studies were heterogeneous, especially with respect to type of intervention, study duration (range: 1 week to 1 year, most up to 8 weeks) and assessed outcomes. Most were RCTs (n=19), and a minority CCTs (n=3) or cross-over trials (n=6). Many studies were small: 15 trials (54%) included 60 participants or less. All studies were judged to be at high or unclear RoB, most often due to lack of blinding. A detailed RoB assessment is presented in [online supplementary tables 3.1.1-3.1.12](#SP1){ref-type="supplementary-material"}

[Table 2](#T2){ref-type="table"} presents an overview of the main results of the most relevant non-pharmacological trials for which the outcomes pain, function, fulfilment of OARSI-OMERACT criteria[@R4] or grip strength could be assessed. Safety outcomes are presented in [online supplementary table 4.1](#SP1){ref-type="supplementary-material"}. If studies were pooled, results are also presented in forest plots ([online supplementary figures S1-S8](#SP1){ref-type="supplementary-material"}).

###### 

Efficacy of main non-pharmacological interventions for hand osteoarthritis from randomised controlled trials/clinical controlled trials

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intervention                                                   Control                               Outcome            Participants (studies), n   Duration                                                                Quality of evidence                                                                            Effect estimate (95%CI)                                        References; comments
  -------------------------------------------------------------- ------------------------------------- ------------------ --------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------
  **Exercise**                                                                                                                                                                                                                                                                                                                                                                              

  Hand exercise                                                  No exercise                           Pain               381 (5)                     12 weeks                                                                GRADE: low                                                                                     SMD −0.27 (−0.47 to −0.07)\*                                   [@R6]; Cochrane review

  Function                                                       369 (4)                               12 weeks           GRADE: low                  SMD −0.28 (−0.58 to 0.02)\*                                             Idem                                                                                                                                                          

  OARSI-OMERACT responder                                        305 (3)                               12 weeks           Not reported                RR 2.8 (1.4 to 5.6)\*                                                   Idem                                                                                                                                                          

  Grip strength                                                  362 (5)                               12 weeks           Not reported                SMD 0.34 (−0.01 to 0.69)\*                                              Idem                                                                                                                                                          

  **Joint protection**                                                                                                                                                                                                                                                                                                                                                                      

  Joint protection                                               No joint protection                   Pain               257 (1)                     26 weeks                                                                RoB: high                                                                                      MD −0.79 (−1.7 to 0.12) on AUSCAN pain scale (range 0--20)\*   [@R7]; adjusted for age, gender, social class, centre, disease duration

  Function                                                       257 (1)                               26 weeks           RoB: high                   MD −0.6 (−1.9 to 1.1) on AUSCAN function scale (range 0--36)\*          Idem                                                                                                                                                          

  OARSI-OMERACT responder                                        257 (1)                               26 weeks           RoB: high                   OR 2.1 (1.1 to 4.0)\*                                                   Idem                                                                                                                                                          

  Grip strength                                                  257 (1)                               26 weeks           RoB: high                   MD −0.47 (−1.9 to 0.94) kg†                                             Idem                                                                                                                                                          

  **Splints**                                                                                                                                                                                                                                                                                                                                                                               

  Thumb splint                                                   Usual care or no intervention         Pain               221 (4)                     4--8 weeks                                                              RoB: high                                                                                      MD −2.9 (−12.2 to 6.5) on 100 mm VAS\*                         [@R9]

  Pain                                                           137 (2)                               13--52 weeks       RoB: high                   MD −17.4 (−25.6 to −9.2) on 100 mm VAS\*                                [@R10]                                                                                                                                                        

  Function                                                       144 (3)                               4 weeks            RoB: high                   SMD 0.24 (−0.11 to 0.60)†                                               [@R8]; effect estimate based on two trials (n=126)[@R9]                                                                                                       

  Function                                                       112 (1)                               52 weeks           RoB: high                   MD −6.3 (−10.9 to −1.7) on Cochin hand function scale (range 0--90)\*   [@R12]                                                                                                                                                        

  Grip strength                                                  95 (2)                                6--8 weeks         RoB: high                   SMD 0.39 (−0.35 to 1.1)\*                                               [@R10]                                                                                                                                                        

  Grip strength                                                  40 (1)                                13 weeks           RoB: high                   MD 0.8 (−3.1 to 4.7) kg\*                                               [@R10]                                                                                                                                                        

  Long thumb splint (MCP+CMC joint)                              Short thumb splint (only CMC joint)   Pain               185 (3)                     2--12 weeks                                                             RoB: high                                                                                      MD −0.85 (−5.1 to 3.4) on 100 mm VAS\*                         [@R13]; Wajon: results after splint period used for pooling

  Function                                                       146 (2)                               9--12 weeks        RoB: high                   MD 1.7 (−0.94 to 4.3)†                                                  [@R13]                                                                                                                                                        

  DIP splint                                                     No intervention                       Pain               26 (1)                      12 weeks                                                                RoB: high                                                                                      Median difference 0.5 (range\                                  [@R21]; outcome: average pain
                                                                                                                                                                                                                                                                                                                             −7 to 3.5, p=0.53) on 10 cm VAS\*                              

  Function                                                       26 (1)                                12 weeks           RoB: high                   No between-group difference                                             [@R21]; no raw data presented                                                                                                                                 

  **Assistive devices**                                                                                                                                                                                                                                                                                                                                                                     

  Assistive device                                               Information provision                 Pain               70 (1)                      12 weeks                                                                RoB: high                                                                                      MD 0.4 (−9.8 to 10.6) on 100 mm VAS†                           [@R22]; adjusted for baseline

  Function                                                       70 (1)                                12 weeks           RoB: high                   MD −0.3 (−0.6 to 0.01) on AUSCAN function scale (range 1--5)\*          [@R22]; adjusted for baseline, COPM scores (primary outcome) also significant improvements\*                                                                  

  **Combination** **programme**                                                                                                                                                                                                                                                                                                                                                             

  Combination programme: education, joint protection, exercise   Education alone                       Pain               321 (3)                     12 weeks                                                                RoB: high                                                                                      MD 0.40 (−0.50 to 1.3) on AUSCAN pain scale (range 0--20)†     [@R7]; effect estimate based on one trial (n=151),[@R26]adjusted for baseline

  Function                                                       321 (3)                               12 weeks           RoB: high                   MD 0.49 (−1.0 to 2.0) on AUSCAN function scale (range 0--36)\*          [@R7]; effect estimate based on one trial (n=151),[@R26]adjusted for baseline                                                                                 

  OARSI-OMERACT responder                                        281 (2)                               12 weeks           RoB: high                   OR 0.82 (0.42 to 1.6)†                                                  [@R7]; effect estimate based on one trial (n=151)[@R26]                                                                                                       

  Grip strength                                                  321 (3)                               12 weeks           RoB: high                   SMD −0.21 (−0.49 to 0.08)†                                              [@R7]; effect estimate based on two trials (n=186)[@R25]                                                                                                      

  **Quality of** **evidence**:                                   GRADE: very low/low\                  GRADE: moderate\   GRADE: high\                                                                                        Effect estimate:                                                                               No effect                                                      Between-group difference
                                                                 RoB: high                             RoB: unclear       RoB: low                                                                                                                                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*In favour of the intervention group.

†In favour of the control group.

AUSCAN, Australian/Canadian Hand Osteoarthritis Index; CMC, first carpometacarpal; COPM, Canadian Occupational Performance Measure; DIP, distal interphalangeal joint; idem, same as above; MCP, metacarpophalangeal joint; MD, mean difference; OA, osteoarthritis; RoB, risk of bias; RR, risk ratio; SMD, standardised mean difference; VAS, visual analogue scale.

In summary, exercise leads to beneficial effects on hand pain, function, joint stiffness and grip strength, although effect sizes are small. Few (non-severe) AEs were reported, showing a signal for increased number of AEs in participants undergoing exercise therapy, in particular increased joint inflammation and hand pain (RR 4.6 (95% CI 0.5 to 39.3); [online supplementary table 4.1](#SP1){ref-type="supplementary-material"}).[@R6]

Joint protection led to a higher proportion of participants being classified as responder to treatment according to OARSI-OMERACT criteria after 6 months, though mean AUSCAN pain and function subscales did not differ between groups.[@R7]

On the short term, thumb base splinting did not lead to pain relief or functional improvement,[@R8] though studies assessing long-term use showed that this was associated with more pain relief and improved function ([online supplementary figures S1-S4](#SP1){ref-type="supplementary-material"}).[@R10] Studies assessed many different types of splints (eg, short or long, custom-made or prefabricated, neoprene or thermoplast or other material) and instructions for use (eg, during activities of daily living, at night, constantly). Only short versus long thumb base splints (ie, including only CMC joint vs both CMC and MCP joint) could formally be compared and were not associated with different clinical outcomes ([online supplementary figures S5-S6](#SP1){ref-type="supplementary-material"}).[@R13] For other splint types or instructions, no consistent benefit of one over another could be identified in RCTs/CCTs or cross-over studies.[@R16] A single study assessed night-time DIP splinting specifically, but did not show improvements in pain, function or pinch strength after 3 months.[@R21]

Use of assistive devices led to small improvements in function, as measured with the patient-specific Canadian Occupational Performance Measure (COPM) and the AUSCAN function subscale, but not in pain.[@R22]

Several studies assessed different combination programmes of multiple non-pharmacological interventions.[@R7] Three trials compared a programme including education, joint protection and hand exercises to education alone, and though no formal meta-analysis could be performed, no between-group differences in pain, function or grip strength could be confirmed ([online supplementary figures S7-S8](#SP1){ref-type="supplementary-material"}).[@R7] The other studies of combination programme were more heterogeneous, especially in the type of intervention studied. Some reported positive effects of the combination versus non-combination interventions, especially on subjective measures like pain,[@R23] and not on more objective measures like hand strength,[@R24] though others reported no between-group differences.[@R15]

Furthermore, application of heat was assessed in three heterogeneous trials, both in design and type of intervention (high RoB). Two studies reported improvements in, for example, pain and grip strength in the intervention group compared with control,[@R29] and one cross-over trial reported no between-group differences.[@R31] Three studies (high RoB) focused on different forms of manual therapy in elderly, severe CMC patients with OA (mean age 81.4 years) and showed positive effects on pain sensitivity and hand strength in the intervention group compared with control, both in the treated, symptomatic hand, and in the contralateral non-treated non-symptomatic hand.[@R32] Finally, six studies (five high RoB, one unclear RoB) assessed different forms of balneotherapy to another active intervention,[@R38] sham intervention[@R41] or usual care.[@R43] The studies comparing balneotherapy to another active intervention or to usual care all report positive effects of balneotherapy on pain, function and hand strength compared with the chosen control group.[@R38] However, balneotherapy (mud application or mineral thermal bath) was not convincingly better than a sham intervention.[@R41]

Pharmacological interventions {#s3-2}
-----------------------------

[Table 3](#T3){ref-type="table"} presents an overview of the characteristics and RoB of the 33 trials of the most relevant pharmacological interventions to inform the 2018 update of the EULAR management recommendations for hand OA. Trials not listed in [table 3](#T3){ref-type="table"} studied topical capsaicin (n=1), topical salicylates (n=2), paracetamol (n=4), glucosamine (n=1), diacerhein (n=1), different herbal formulations (n=3), anti-interleukin-1 (n=1), clodronate (n=1), several types of periarticular injections (n=3), intra-articular hyaluronic acid (n=9), other intra-articular therapies (n=2), folate/cobalamin supplementation (n=1), apremilast (n=1), galactosaminoglycuronglycan sulfate (n=1), and pregabalin and duloxetine (n=1). A description can be found in [online supplementary tables (3.2.2, 3.2.4, 3.2.6, 3.2.10, 3.2.12, 3.2.15, 3.2.17, 3.2.22)](#SP1){ref-type="supplementary-material"}.

###### 

Characteristics of studies of main pharmacological interventions (n=33 studies)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RoB                                                         Study                             Design                     Intervention                                                                Frequency, duration                     N                                       OA location, definition                            Women (%)        Age (years)     Primary outcome
  ----------------------------------------------------------- --------------------------------- -------------------------- --------------------------------------------------------------------------- --------------------------------------- --------------------------------------- -------------------------------------------------- ---------------- --------------- --------------------------------------
  **Topical NSAIDs**                                                                                                                                                                                                                                                                                                                                                       

                                                              Altman *et al* 2009[@R52]         RCT                        Topical diclofenac gel 1%                                                   4 per day, 8 weeks                      198                                     ACR, Rx KL1--3                                     77               63.6 (10.3)     VAS pain, AUSCAN, VAS patient global

  Topical placebo cream                                       187                               77                         64.7 (9.6)                                                                                                                                                                                                                                      

                                                              Graber *et al* 1997[@R39]         RCT                        Topical ibuprofen cream                                                     3 per day, 2 weeks                      57                                      ACR or clinical diagnosis isolated CMC OA          91               65.8 (8.6)      FIHOA

  Berthollet treatment (local steam bath and finger shower)   Daily, 3 weeks                    59                         86                                                                          63.2 (10.0)                                                                                                                                                         

  Michalsen *et al* 2008[@R92]﻿                               RCT                               Diclofenac gel 10 mg/g     2 per day, 4 weeks                                                          16                                      CMC, clinical diagnosis and Rx damage   100                                                64.3 (9.1)       VAS pain        

  Medicinal leeches                                           Once in 4 weeks                   16                         64.1 (6.4)                                                                                                                                                                                                                                      

                                                              Romero *et al* 2013[@R55]         RCT                        Topical diclofenac gel 2%                                                   3 per day, 4 weeks                      65                                      ACR                                                86               62 (10.2)       NR

  Topical herbal cream                                        65                                95                                                                                                                                                                                                                                                                         

                                                              Talke *et al* 1985[@R50]          RCT                        Topical etofenamate 100 mg/g                                                3 per day, 3 weeks                      30                                      IP, clinical diagnosis, \'activated\'              83               64.3 (13.5)     NR

  Oral indomethacin 150 mg/day                                3 weeks                           30                         90                                                                          63.3 (11.0)                                                                                                                                                         

                                                              Widrig *et al* 2007[@R54]         RCT                        Topical ibuprofen cream 5%                                                  3 per day, 3 weeks                      99                                      ACR                                                61               64 (11.4)       VAS pain, FIHOA

  Topical arnica cream 50%                                    105                               67                         64 (12.0)                                                                                                                                                                                                                                       

                                                              Zacher *et al* 2001[@R51]         RCT                        Topical diclofenac gel 1%                                                   4 per day, 3 weeks                      165                                     IP, clinical diagnosis, \'activated\'              86               60.7 (9.4)      VAS pain improve≥40%

  Oral ibuprofen 1200 mg/day                                  3 weeks                           156                        90                                                                          63.2 (9.4)                                                                                                                                                          

  **Oral NSAIDs**                                                                                                                                                                                                                                                                                                                                                          

                                                              Dreiser *et al* 1993[@R62]        RCT                        Ibuprofen 800 mg/day                                                        2 weeks                                 30                                      Rx damage, pain exacerbation                       80               58.5 (1.7)      NR

  Placebo                                                     30                                90                         60.3 (2.0)                                                                                                                                                                                                                                      

                                                              Grifka *et al* 2004[@R63]         RCT                        Lumiracoxib 200 mg/day                                                      4 weeks                                 205                                     ACR                                                82               62.0 (12.1)     VAS pain

  Lumiracoxib 400 mg/day                                      193                               83                         61.0 (12.4)                                                                                                                                                                                                                                     

  Placebo                                                     196                               83                         62.7 (11.7)                                                                                                                                                                                                                                     

                                                              Muratore *et al* 2004[@R65]\      RCT                        Ketoprofen lysine salt 160 mg/day+glucosamine+chondroitin sulfate           20 days                                 30                                      Hand, NR                                           100              NR              NR
                                                              (A)                                                                                                                                                                                                                                                                                                          

  Glucosamine+chondroitin sulfate                             28                                                                                                                                                                                                                                                                                                           

                                                              Rovetta *et al*,2001-B[@R49]      CCT                        Dexketoprofen-trometamol 50 mg/day                                          3 weeks                                 35                                      ACR, \'active OA\'                                 86               57.7 (3.4)      Morning stiffness (WOMAC)

  No intervention                                             19                                63                                                                                                                                                                                                                                                                         

                                                              Rovetta *et al,* 2001-A[@R48]     CO\                        Dexketoprofen-trometamol 50 mg/day                                          13 days                                 36                                      ACR, \'active OA\'                                 NR               NR              Morning stiffness and pain (WOMAC)
                                                                                                (WA-)                                                                                                                                                                                                                                                                      

  Paracetamol 1000 mg/day                                                                                                                                                                                                                                                                                                                                                  

                                                              Seiler 1983[@R64]                 RCT                        Meclofenamate sodium 300 mg/day                                             4 weeks                                 22                                      Clinical diagnosis,≥1 inflamed DIP and Rx damage   95               62.5 (34--77)   NR

  Placebo                                                     19                                84                         65.0 (49--80)                                                                                                                                                                                                                                   

                                                              Talke 1985[@R50]                  RCT                        Oral indomethacin 150 mg/day                                                3 weeks                                 30                                      IP, clinical diagnosis, \'activated\'              83               64.3 (13.5)     NR

  Topical etofenamate 100 mg/g                                3 per day, 3 weeks                30                         90                                                                          63.3 (11.0)                                                                                                                                                         

                                                              Zacher *et al* 2001[@R51]         RCT                        Oral ibuprofen 1200 mg/day                                                  3 weeks                                 156                                     IP, clinical diagnosis,\'activated\'               90               63.2 (9.4)      VAS pain improve≥40%

  Topical diclofenac gel 1%                                   4 per day, 3 weeks                165                        86                                                                          60.7 (9.4)                                                                                                                                                          

  **Chondroitin sulfate**                                                                                                                                                                                                                                                                                                                                                  

                                                              Gabay *et al* 2011[@R66]          RCT                        Chondroitin sulfate 800 mg/day                                              6 months                                80                                      ACR                                                73               63.9 (8.5)      VAS pain, FIHOA

  Placebo                                                     82                                76                         63.0 (7.2)                                                                                                                                                                                                                                      

                                                              Verbruggen 2002[@R44]             RCT                        Chondroitin polysulphate 50 mg/day intramuscularly                          3 years                                 66                                      IP, clinical diagnosis and Rx damage               91               55.2 (6.7)      Rx progression

  Placebo intramuscularly                                     64                                97                         56.1 (9.2)                                                                                                                                                                                                                                      

  RCT                                                         Chondroitin sulfate 1200 mg/day   3 years                    44                                                                          IP, clinical diagnosis and Rx damage    91                                      57.6 (7.1)                                         Rx progression                   

  Placebo                                                     48                                88                         55.9 (8.9)                                                                                                                                                                                                                                      

  **Intra-articular glucocorticoids**                                                                                                                                                                                                                                                                                                                                      

                                                              Bahadir*et al* 2009[@R73]         RCT                        Glucocorticoid i.a. 20 mg/0.5 mL                                            Once                                    20                                      CMC, Rx E-L stage II--III                          100              62.9 (9.1)      NR

  Hyaluronic acid i.a. 5 mg/0.5 mL                            1 per week, 3 weeks               20                         60.8 (7.3)                                                                                                                                                                                                                                      

                                                              Fuchs *et al* 2006[@R74]          RCT                        Glucocorticoid i.a. 10 mg/1 mL                                              1 per week, 3 weeks                     28                                      CMC, clinical diagnosis and Rx KL\>0               80               Median 61.0     NR

  Hyaluronic acid i.a. 10 mg/1 mL                             28                                Median 59.5                                                                                                                                                                                                                                                                

  Heyworth *et al* 2008[@R68]﻿                                RCT                               Glucocorticoids i.a.1 mL   Once+1 i.a. placebo, 2 weeks                                                22                                      CMC, Rx E-L stage I--IV                 90                                                 60 (9.4)         NR              

  Hyaluronic acid i.a. 8 mg/1 mL                              1 per week, 2 weeks               28                         80                                                                          65 (10.6)                                                                                                                                                           

  Placebo i.a. (1 mL, saline)                                 1 per week, 2 weeks               18                         89                                                                          64 (8.5)                                                                                                                                                            

                                                              Jahangiri 2014[@R93]              RCT                        Gluocorticoid i.a. 40 mg/0.5 mL+0.5 mL lidocaine                            Once+2 i.a. placebo, 3 weeks            30                                      CMC, clinical diagnosis and Rx E-L stage\>I        70               63.3 (10.1)     VAS pain

  Dextrose i.a. 100 mg/0.5 mL+0.5 mL lidocaine                1 per week, 3 weeks               30                         77                                                                          63.9 (9.4)                                                                                                                                                          

                                                              Mandl,*et al*\                    RCT                        Glucocorticoid i.a. 40 mg/1 mL                                              Once+1 i.a. placebo,2 weeks             65                                      CMC, clinical diagnosis and Rx KL\>0               68               66.5 (45--89)   NR
                                                              2012[@R69](A)                                                                                                                                                                                                                                                                                                

  Hyaluronic acid i.a. 8 mg/1 mL                              1 per week, 2 weeks               62                                                                                                                                                                                                                                                                         

  Placebo i.a. (1 mL, bupivacaine)                            1 per week, 2 weeks               61                                                                                                                                                                                                                                                                         

                                                              Meenagh *et al* 2004[@R70]        RCT                        Glucocorticoid i.a. 5 mg/0.25 mL                                            Once                                    20                                      CMC, NR                                            95               60.6 (41--71)   VAS pain improve≥20%

  Placebo i.a. (0.25 mL, saline)                              20                                85                         59.3 (46--69)                                                                                                                                                                                                                                   

                                                              Monfort *et al* 2014[@R75]        RCT                        Glucocorticoid i.a. 3 mg/0.5 mL                                             1 per week, 3 weeks                     40                                      CMC, clinical diagnosis and Rx KL1--3              88               62.8 (8.7)      FIHOA

  Hyaluronic acid i.a. 5 mg/0.5 mL                            48                                                                                                                                                                                                                                                                                                           

                                                              Spolidoro,*et al*\                RCT                        Glucocorticoid i.a.4 mg/0.2 mL (DIP) or 6 mg/0.3 mL(PIP)+0.1 mL lidocaine   Once                                    30                                      IP, clinical diagnosis and Rx osteophyte           100              60.7 (9.1)      VAS pain, VAS joint swelling
                                                              2015[@R71]                                                                                                                                                                                                                                                                                                   

  Placebo i.a. (0.1 mL, lidocaine)                            30                                93                         60.7 (7.3)                                                                                                                                                                                                                                      

                                                              Stahl *et al* 2005[@R76]          RCT                        Glucocorticoid i.a. 40 mg/1 mL                                              Once                                    25                                      CMC, Rx E-L stage II                               84               62 (50--91)     NR

  Hyaluronic acid i.a. 15 mg/1 mL                             27                                92.5                       62 (37--80)                                                                                                                                                                                                                                     

  **Oral glucocorticoids**                                                                                                                                                                                                                                                                                                                                                 

                                                              Kvien *et al* 2008[@R81]          RCT                        Prednisone 3 mg/day+dipyridamole 200 mg/day                                 6 weeks                                 42                                      ACR, Rx KL\>1                                      93               61.1 (5.0)      AUSCAN pain

  Placebo                                                     41                                93                         59.6 (5.3)                                                                                                                                                                                                                                      

                                                              Wenham *et al* 2012[@R82]         RCT                        Prednisone 5 mg/day                                                         4 weeks                                 35                                      ACR, Rx KL\>0                                      74               61.9 (6.6)      VAS pain

  Placebo                                                     35                                89                         61.1 (9.0)                                                                                                                                                                                                                                      

  **Hydroxychloroquine**                                                                                                                                                                                                                                                                                                                                                   

                                                              Basoski *et al* 2015[@R83](A)     RCT                        Hydroxychloroquine 400 mg/day                                               24 weeks                                98                                      ACR                                                86               57              VAS pain

  Placebo                                                     98                                                                                                                                                                                                                                                                                                           

                                                              Kingsbury,*et al* 2016[@R84](A)   RCT                        Hydroxychloroquine 200--400 mg/day                                          1 year                                  124                                     ACR                                                NR               NR              NRS pain

  Placebo                                                     124                                                                                                                                                                                                                                                                                                          

                                                              McKendry *et al* 2001[@R59](A)    RCT                        Hydroxychloroquine 400 mg/day                                               24 weeks                                29                                      Hand, NR                                           NR               NR              NR

  Paracetamol 3900 mg/day                                     29                                                                                                                                                                                                                                                                                                           

  Placebo                                                     30                                                                                                                                                                                                                                                                                                           

  **TNF inhibitors**                                                                                                                                                                                                                                                                                                                                                       

                                                              Aitken *et al* 2017[@R46](A)      CO (WA+)                   Adalimumab 40 mg subcutaneously                                             2 subcutaneously per 2 weeks,12 weeks   43                                      ACR, erosive (Rx erosion), MRI synovitis           77               61 (8.4)        AUSCAN pain

  Placebo subcutaneously                                                                                                                                                                                                                                                                                                                                                   

                                                              Chevalier *et al* 2015[@R85]      RCT                        Adalimumab 40 mg subcutaneously                                             Once 2 subcutaneously,2 weeks           42                                      ACR, Rx damage IPs                                 87               62.8 (6.9)      VAS pain improve≥50%

  Placebo subcutaneously                                      43                                83                         62.2 (7.0)                                                                                                                                                                                                                                      

                                                              Kloppenburg *et al* 2016[@R47]\   RCT                        Etanercept 25--50 mg subcutaneously                                         1 subcutaneously per week, 1 year       45                                      IP, ACR, erosive (Rx erosion IP)                   82               59.4 (6.5)      VAS pain
                                                              (A)                                                                                                                                                                                                                                                                                                          

  Placebo subcutaneously                                      45                                80                         60.1 (8.7)                                                                                                                                                                                                                                      

                                                              Verbruggen *et al* 2012[@R45]     RCT                        Adalimumab 40 mg subcutaneously                                             1 subcutaneously per 2 weeks,\          30                                      IP, ACR, erosive (Rx erosion IP)                   87               61.9 (6.1)      Rx progression
                                                                                                                                                                                                       1 year                                                                                                                                                              

  Placebo subcutaneously                                      30                                83                         60.7 (6.9)                                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are mean (SD) or median (min-max). Colours denote RoB (green:low, yellow: unclear, red: high). (A) indicates conference abstract.

ACR, American College of Rheumatology; AUSCAN, Australian/Canadian Hand Osteoarthritis Index; CCT, clinical controlled trials; CMC, first carpometacarpal; CO, cross-over trial; FIHOA, Functional Index for Hand OsteoArthritis; i.a., intra-articular; IP, interphalangeal joint; NR, not reported; NRS, numerical rating scale; NSAID, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; RCT, randomised controlled trial; TNF, tumour necrosis factor; VAS, visual analogue scale; WA, wash-out period; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

The longest trial lasted up to 3 years, though most trials had a duration of 3 weeks. Most studies focused on clinical outcomes, while structure modification was the primary outcome of two trials.[@R44] The majority were RCTs (n=30), and few were set-up as CCTs (n=1) or cross-over trials (n=2). Seven trials specifically included participants with signs of \'inflammatory OA\', all investigating anti-inflammatory agents (ie, NSAIDs, glucocorticoids and anti-TNF).[@R45] Compared with non-pharmacological interventions, less studies were small (n≤60; 15 trials, 45%). Twelve studies (36%) were at low RoB. Reason to judge studies to be at high or unclear RoB was most often due to problems with randomisation or blinding, and for six studies only a conference abstract was available thus RoB remained unclear. The detailed RoB assessment is presented in [online supplementary (3.2.1--3.2.23)](#SP1){ref-type="supplementary-material"}.

[Table 4](#T4){ref-type="table"} presents an overview of the main results of the most relevant pharmacological trials for which the outcomes pain, function, fulfilment of OARSI-OMERACT criteria[@R4] or grip strength could be assessed. Safety outcomes are presented in [online supplementary table 4.2](#SP1){ref-type="supplementary-material"}. Forest plots of pooled results are presented in [online supplementary figures S9-S20](#SP1){ref-type="supplementary-material"}.

### Topical pharmacological interventions {#s3-2-1}

###### 

Efficacy of main pharmacological interventions for hand osteoarthritis from randomised controlled trials/clinical controlled trials

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intervention                       Control                   Outcome            Participants (studies), n   Duration                    Specific OA location or type                                       Quality of evidence                                         Effect estimate (95%CI)                    References; comments
  ---------------------------------- ------------------------- ------------------ --------------------------- --------------------------- ------------------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------
  **Topical NSAIDs**                                                                                                                                                                                                                                                                                                

  Topical NSAID                      Topical placebo           Pain               385 (1)                     8 weeks                     --                                                                 RoB: low                                                    MD −5.9 (−11.7 to −0.06) on 100 mm VAS\*   [@R52]

  Function                           385 (1)                   8 weeks            --                          RoB: low                    MD −7.3 (−12.9 to −1.7) on AUSCAN function scale (range 0--36)\*   [@R52]                                                                                                 

  OARSI-OMERACT response             385 (1)                   8 weeks            --                          RoB: low                    RR 1.2 (0.99 to 1.4)\*                                             [@R52]                                                                                                 

  Topical NSAID                      Oral NSAID                Pain               381 (2)                     3 weeks                     \'Activated\' IP OA                                                RoB: low                                                    SMD −0.05 (−0.27 to 0.17)\*                [@R50]; effect estimate based on one trial (n=321)[@R51]; same studies as previous SLR[@R1]

  Grip strength                      381 (2)                   3 weeks            \'Activated\' IP OA         RoB: low                    MD −0.01 (−0.03 to 0.01) bar\*                                     [@R50]; effect estimate based on one trial (n=321)[@R51]                                               

  **Oral NSAIDs**                                                                                                                                                                                                                                                                                                   

  Oral NSAID                         Placebo                   Pain               695 (3)                     2--4 weeks                  --                                                                 RoB: low                                                    SMD 0.40 (0.20 to 0.60)\*                  [@R62]; effect estimate based on two trials with ibuprofen 800 mg and lumiracoxib 200--400 mg (n=654)[@R62]; same studies as previous SLR[@R1]

  Function                           695 (3)                   2--4 weeks         --                          RoB: low                    SMD 0.17 (−0.03 to 0.36)\*                                         Idem                                                                                                   

  **Chondroitin** **sulfate**                                                                                                                                                                                                                                                                                       

  Chondroitin sulfate                Placebo                   Pain               162 (1)                     26 weeks                    --                                                                 RoB: low                                                    MD −8.7 (p=0.016) on 100 mm VAS\*          [@R66]

  Function                           162 (1)                   26 weeks           --                          RoB: low                    MD −2.1 (p=0.008) on FIHOA (range 0--30)\*                         [@R66]                                                                                                 

  Grip strength                      162 (1)                   26 weeks           --                          RoB: low                    MD 1.9 (−0.02 to 3.8) kg\*                                         [@R66]                                                                                                 

  **Intra-articular therapies**                                                                                                                                                                                                                                                                                     

  Intra-articular glucocorticoids    Intra-articular placebo   Pain               206 (3)                     26 weeks                    CMC                                                                RoB: low (1), unclear (1)                                   MD −3.6 (−13.9 to 6.8) on 100 mm VAS\*     [@R68]; effect estimate based on two trials (n=166)[@R69]

  Function                           166 (2)                   26 weeks           CMC                         RoB: unclear                MD −1.5 (−6.3 to 3.3) on DASH (range 0--100)\*                     [@R68]; effect estimate based on one trial (n=126)[@R69]                                               

  Intra-articular glucocorticoids    Intra-articular placebo   Pain               60 (1)                      12 weeks                    IP                                                                 RoB: low                                                    MD −18.0 (−33.5 to −2.6) on 100 mm VAS\*   [@R71]; outcome: pain on movement; for pain in rest no between-group differences observed

  Function                           60 (1)                    12 weeks           IP                          RoB: low                    MD −4.4 (--9.4 to 0.56) on AUSCAN function scale (range 0--36)\*   [@R71]                                                                                                 

  Grip strength                      60 (1)                    12 weeks           IP                          RoB: low                    MD 0.98 (−2.6 -- to 4.5) kg\*                                      [@R71]                                                                                                 

  Intra-articular hyaluronic acid    Intra-articular placebo   Pain               235 (3)                     26 weeks                    CMC                                                                RoB: unclear                                                MD 3.3 (−5.2 to 11.8) on 100 mm VAS†       [@R68]; effect estimate based on one trial (n=123)[@R69]

  Function                           235 (3)                   26 weeks           CMC                         RoB: unclear                MD −2.1 (6.3 to 2.1) on DASH (range 0--100)\*                      Idem                                                                                                   

  **Hydroxychloroquine**                                                                                                                                                                                                                                                                                            

  Hydroxychloroquine                 Placebo                   Pain               503 (3)                     24--52 weeks                --                                                                 RoB: unclear                                                MD 2.9 (−3.4 to 9.2) on 100 mm VAS†        [@R59]; Effect estimate based on two trials (n=307)[@R59]

  Function                           444 (2)                   24--52 weeks       --                          RoB: unclear                MD −0.79 (−2.4 to 0.78) on AUSCAN function scale (range 0--36)†    [@R83]; effect estimate based on one trial (n=248)[@R84]                                               

  Grip strength                      248 (1)                   52 weeks           --                          RoB: unclear                MD 0.95 (−0.82 to 2.72)kg†                                         [@R84]                                                                                                 

  **TNF inhibitors**                                                                                                                                                                                                                                                                                                

  TNF inhibitor                      Placebo                   Pain               235 (3)                     24--52 weeks                Erosive OA (2/3 trials)                                            RoB: low                                                    MD −4.9 (−12.5 to 2.8) on 100 mm VAS\*     [@R45]; effect estimate based on two trials (n=175)[@R85]

  Function                           235 (3)                   24--52 weeks       Erosive OA (2/3 trials)     RoB: low (1), unclear (1)   SMD −0.02 (−0.35 to 0.32)\*                                        [@R45]; effect estimate based on two trials (n=145)[@R45]                                              

  Grip strength                      150 (2)                   52 weeks           Erosive OA                  RoB: low (1), unclear (1)   MD 0.70 (−0.59 to 2.0)kg\*                                         [@R45]; effect estimate based on one trial (n=60)[@R45]                                                

  **Quality** **of** **evidence**:   GRADE: very low/low\      GRADE: moderate\   GRADE: high\                                            Effect estimate:                                                   No effect                                                   Between-group difference                   
                                     RoB: high                 RoB: unclear       RoB: low                                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*In favour of the intervention group. †In favour of the control group.

AUSCAN, Australian/Canadian hand osteoarthritis index; CMC, first carpometacarpal joint; DASH, Disabilities of the Arm, Shoulder and Hand; DIP, distal interphalangeal joint; idem, same as above; IP, interphalangeal joint; MD, mean difference; NSAID, non-steroidal anti-inflammatory drug; OA, osteoarthritis; RoB, risk of bias; RR, risk ratio; SLR, systematic literature review; SMD, standardised mean difference; TNF, tumour necrosis factor; VAS, visual analogue scale.

Topical diclofenac gel was shown to be superior to placebo in a large RCT (low RoB), leading to small improvements in pain and function, and not more AEs, after 8 weeks.[@R52] Topical NSAIDs led to similar pain relief as oral NSAIDs,[@R50] yet lower risk of any AE (RR 0.40 (95% CI 0.09 to 1.74)),[@R50] gastrointestinal AEs (RR 0.64 (0.35 to 1.20)),[@R51] severe AEs (RR 0.54 (0.17 to 1.71)),[@R51] and withdrawals due to AEs (RR 0.15 (0.03 to 0.63)) ([online supplementary table 5.2, figures S9-S11](#SP1){ref-type="supplementary-material"}).[@R51] Pooled safety data from two RCTs comparing topical diclofenac gel to placebo in patients with hand OA showed similar and low rates of AEs in subgroups at low versus high risk of NSAID-related AEs (ie, age ≥65 years, and with comorbid hypertension, type 2 diabetes or cerebrovascular or cardiovascular disease).[@R53] A trial (low RoB) comparing topical ibuprofen cream to arnica cream found no between-group differences.[@R54] Two studies (one high RoB, one unclear RoB) comparing topical NSAIDs with a non-pharmacological treatment reported superiority of the comparator.[@R39] Topical capsaicin was assessed in one RCT (unclear RoB), reporting better pain relief than placebo at the cost of increased risk of local AEs (burning and stinging sensation, RR 3.1 (95% CI 1.1 to 8.5)), which likely also compromised the trial's success of blinding.[@R56] A single application of topical salicylates was reported in two trials (high RoB) to lead to improvements in pain and stiffness, but also numerically more local AEs.[@R57]

### Oral analgesics {#s3-2-2}

Paracetamol was included as a treatment arm in three conference abstracts (unclear RoB) and one cross-over trial (high RoB), in various dosages and for different duration.[@R48] Three trials intended paracetamol to be the control group. One trial (unclear RoB) included a placebo arm, and reports no between-group difference in pain or morning stiffness.[@R59] Paracetamol was not superior to any of the active comparators.[@R48]

Oral NSAIDs lead to moderate improvements in pain and function compared with no intervention,[@R49] placebo[@R62] and other active interventions (glucosamine/chondroitin sulfate,[@R65] paracetamol[@R48]).

### Nutraceuticals {#s3-2-3}

The effectiveness of chondroitin sulfate was studied in two papers. One trial (low RoB) focused on clinical outcomes after 6 months, reporting beneficial effects on pain and function compared with placebo.[@R66] The other study (high RoB) assessed structural outcomes in two long-term trials (published in one paper), assessing chondroitin sulfate and chondroitin polysulphate.[@R44] Only for chondroitin polysulphate, a preparation not commercially available, less erosive damage after 3 years was reported and not for chondroitin sulfate. The trials did not report higher risk of sAEs in the intervention groups.

Glucosamine is reported to have beneficial effects on pain and function after 6 weeks in an RCT (unclear RoB) published as conference abstract (no raw data provided).[@R61]

Diacerhein was not better than placebo for pain relief or any of the other secondary outcomes in a study (unclear RoB) of Korean patients with hand OA, while more (mild) AEs were reported in the intervention group, especially discoloration of urine (88% vs 20%) and abdominal pain (31% vs 14%), but remarkably not diarrhoea (21% vs 20%).[@R67]

### Intra-articular treatments {#s3-2-4}

Several intra-articular therapies were assessed, of which glucocorticoids and hyaluronic acid are the most commonly used. Intra-articular injection of glucocorticoids in the thumb base was not more beneficial than placebo with respect to pain and function ([online supplementary figures S12-13](#SP1){ref-type="supplementary-material"}),[@R68] while in one study (low RoB) participants reported less pain during movement and soft swelling after intra-articular glucocorticoid injection in IP joints.[@R71] However, the latter study did not find beneficial effects on pain in rest or function.

Intra-articular injection of hyaluronic acid in the thumb base did not lead to improvements in pain or function compared with placebo ([online supplementary figure S14](#SP1){ref-type="supplementary-material"}).[@R68] Six trials (four high RoB, two unclear RoB) compared intra-articular thumb base injection of glucocorticoids to hyaluronic acid, but no consistent beneficial effect of one treatment over the other could be shown.[@R68] Single studies (two high RoB, two unclear RoB) assessed alternative dosages (ie, one, two or three hyaluronic acid injections,[@R77] low vs high molecular weight hyaluronic acid[@R78]) and therapies (ie, intra-articular infliximab,[@R79] dextrose[@R80]) and are not described in depth.

### Glucocorticoids and conventional or biological DMARDs {#s3-2-5}

Short-term treatment with low-dose oral glucocorticoids were evaluated in two RCTs (low RoB). Six-week treatment with prednisolone/dipyridamole led to more improvement in pain (MD 12.3 (95% CI 3.0 to 21.5) on 100 mm VAS), at the cost of more withdrawals due to AEs (38% vs 15%), mostly due to headache.[@R81] In a trial of 4-week treatment with prednisolone 5 mg, however, no between-group differences were observed (eg, 100 mm VAS pain 19.9 mm in prednisolone vs 16.8 mm in placebo group).[@R82] Results could not be combined due to clinical heterogeneity and remain inconclusive.

Three RCTs (unclear RoB), only published as conference abstracts, show that hydroxychloroquine does not have beneficial effects on pain ([online supplementary figure S15](#SP1){ref-type="supplementary-material"}), function, grip strength or radiographic progression (only assessed by Kingsbury *et al*).[@R59] One trial also included a paracetamol arm and found no between-group differences compared with hydroxychloroquine on pain (MD 2.5 (95% CI −9.9 to 14.9) on 100 mm VAS, in favour of paracetamol).[@R59]

Four studies (two unclear RoB, two low RoB) assessed the efficacy of different TNF inhibitors (adalimumab[@R45] and etanercept[@R47]), but no beneficial effect over placebo could be shown on pain, function or grip strength ([online supplementary figures S16-20](#SP1){ref-type="supplementary-material"}). Two studies (one unclear RoB, one low RoB) report less erosive radiological progression after 1 year in treated joints with soft tissue swelling at baseline (no data to pool).[@R45] One RCT (low RoB) and one cross-over trial (unclear RoB) report no between-group differences in MRI synovitis, while only the RCT found a decrease in bone marrow lesions and the cross-over trial did not.[@R46]

Surgical interventions {#s3-3}
----------------------

A Cochrane review summarised all available trials of thumb base surgery.[@R88] No trials compared surgery to sham surgery or non-operative treatment. The trials all compared different surgical interventions for thumb base OA. Most trials compared trapeziectomy with and without ligament reconstruction tendon interposition (LRTI), but there was no difference in pain (three trials with 162 participants, MD −2.8 (95% CI −9.8 to 4.2) on 100 mm VAS) or function (three trials with 211 participants, SMD 0.01 (95% CI −0.30 to 0.32)), while the risk for more complications was increased in the trapeziectomy with LRTI groups (RR 1.9 (95% CI 0.96 to 3.7)). Single, low-quality studies compared other surgical interventions to each other, but did not show that one intervention was clearly superior over another in terms of efficacy or complication rate. Most importantly, compared with trapeziectomy, both arthrodesis (one trial, 37 participants) and joint replacement surgery (one trial, 26 participants) did not lead to different clinical outcomes. No studies of IP joint surgery could be included in our review.

Discussion {#s4}
==========

This SLR summarises the current evidence for efficacy and safety of all non-pharmacological, pharmacological and surgical treatments for hand OA. Non-pharmacological treatments that were shown to result in symptom relief included hand exercise and prolonged splinting of the thumb base, while single trials showed positive results for joint protection and use of assistive devices. However, the RoB in most trials was high, mainly due to lack of blinding and effect sizes were modest. Pharmacological treatments that most evidently proved to be efficacious in relieving symptoms were NSAIDs, both topical and oral preparations, as assessed in high-quality trials. Single trials, also judged to be at low RoB, reported beneficial results for chondroitin sulfate and intra-articular injections of glucocorticoids in interphalangeal OA. Also for pharmacological interventions, effect sizes were modest, as considered using the cut-offs proposed by Cohen *et al* (ie, 0.2 representing a small,\>0.5 a moderate and \>0.8 a large effect).[@R89] The effect of oral NSAIDs on pain, with an SMD of 0.4, was the largest effect. Taking an effect size of 0.37 as a minimal clinically important difference (MCID; based on the median MCID in four recent OA trials[@R90]), corresponding to 9 mm on a 100 mm VAS, only the effects of prolonged thumb base splinting, oral NSAIDs and intra-articular glucocorticoid injections in interphalangeal joints crossed the margin of clinical meaningful difference. Promising pharmacological treatments for which no clear beneficial effect was demonstrated include paracetamol, intra-articular injections of glucocorticoids or hyaluronic acid in the thumb base joint, low-dose oral glucocorticoids, hydroxychloroquine and TNF inhibitors. Disease-modifying properties, especially radiographic progression, were studied in only a few trials. No convincing effects were found for the formulations investigated, namely chondroitin sulfate (one trial) and TNF inhibitors (two trials). A signal for less erosive damage after 1 year of treatment with anti-TNF was reported in subgroup analyses of joints with clinical signs of inflammation at baseline in two separate trials, yet studies powered for this research question have not been performed to confirm this finding.

Safety was also evaluated in this SLR, though it should be noted that this outcome is best studied in large long-term observational studies with high-quality follow-up since RCTs are usually underpowered to assess this outcome and include a more selected population. Although we aimed to include observational studies for this purpose, we did not find any with our search strategy. Based on this SLR, it is therefore not possible to draw strong conclusions on the safety aspect of many of the assessed therapies. Importantly, the included trials of topical and oral NSAIDs showed that, while no difference in efficacy could be proven, topical NSAIDs were indeed associated with less AEs than oral NSAIDs. Furthermore, no increased risk of AEs was shown for topical NSAIDs compared with placebo. These observations support topical NSAIDs as a useful option for first-line pharmacological treatment. Regarding surgical options, no specific intervention for thumb base OA appeared more effective than another, although in general more complex procedures led to more complications.

The trials included in this review were rather heterogeneous in many aspects, for example in the type of intervention, study duration, and assessed outcomes. This precluded meta-analysis in most instances. Some more recently published trials assessed more of the outcome measures summarised in the OMERACT core set for domains in clinical trials for hand OA.[@R3] A core set for the instruments best used to measure these core domains is still underway. It may be expected that such a core set of instruments will help to harmonise outcome assessment in future clinical trials, which will ultimately improve the assessment of new treatment options.

Despite the large increase in the amount of trials published in the field of hand OA since the previous EULAR management recommendations in 2007 (39 out of 50 and 43 out of 64 included trials of non-pharmacological and pharmacological therapies, respectively, were published in 2007 or later), some important questions remain. For example, placebo-controlled trials of thumb base splints, paracetamol, tramadol and surgery (both for thumb base and interphalangeal OA) are lacking. Moreover, while some trials specifically include a subset of participants with OA of the thumb base, or with \'inflammatory\' or \'activated\' (finger) OA, more trials targeting specific subsets of patients expected to respond to the investigated treatment are needed. Furthermore, many studies were assessed to be at high RoB, often due to lack of blinding or inadequate method of randomisation. So although the number of trials may have increased, their quality is not consistent. For some interventions, especially non-pharmacological therapies, it is difficult to perform a double-blind trial, and therefore the evidence currently available is probably the best we can get. Recently, the Consolidated Standards of Reporting Trials has issued a statement addressing methodological issues specific to trials of non-pharmacological treatments to provide more guidance in this respect.[@R91] However, other interventions, especially pharmacological therapies, are more easily studied in a double-blind fashion, and therefore, well-performed trials are needed and may change the conclusions of this review, for example, for paracetamol.

This SLR has a few strengths, most importantly the methodological rigour with which it was performed, and the presentation of a comprehensive summary of the vast amount of data on the management of hand OA that has accrued so far. However, some limitations have to be acknowledged. Study selection and data extraction was performed by one reviewer author, whereas this should ideally be performed by two independent persons. Many studies were only published as a conference abstract at the time of manuscript preparation, precluding an assessment of the RoB (now categorised as 'unclear').
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